JP Morgan Chase
VYNT

JP Morgan Chase’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

JP Morgan Chase’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-5
Closed – – 6123
2018
Q4 		$0 Buy
+5
New +$421 ﹤0.01% 6017
2016
Q3 		– Sell
-23
Closed -$7K – 4894
2016
Q2 		$7K Buy
+23
New +$8.09K ﹤0.01% 4408

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $169M AUM 12.21% 1-Year Est. Return
DM
Diker Management New York $130M AUM 97.77% 1-Year Est. Return
FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JP Morgan Chase's VYNT Position: Q1 2019 in Review

JP Morgan Chase sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q1 2019, closing a stake of 5 shares.

JP Morgan Chase first reported a position in VYNT in Q2 2016 and held it in 2 quarters. The position peaked at $7K in Q2 2016. 24 funds tracked by Wall St. Rank hold VYNT as of Q1 2019.

  • JP Morgan Chase reported no remaining Vyant Bio, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • JP Morgan Chase sold 5 Vyant Bio, Inc. Common Stock shares in Q1 2019.
  • JP Morgan Chase first reported a position in Vyant Bio, Inc. Common Stock in Q2 2016 and held it in 2 quarters.
  • JP Morgan Chase's Vyant Bio, Inc. Common Stock position peaked at $7K in Q2 2016.
  • 24 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q1 2019.

Based on JP Morgan Chase's 13F filing for Q1 2019, filed 7 May 2019.